Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus PRAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus PRAZOSIN HYDROCHLORIDE.
FLOMAX vs PRAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Prazosin is a quinazoline derivative that acts as a selective, competitive antagonist at postsynaptic alpha-1 adrenergic receptors. It blocks the binding of norepinephrine, thereby inhibiting vasoconstriction and reducing peripheral vascular resistance, leading to decreased blood pressure. It also relaxes smooth muscle in the prostate and bladder neck, improving urine flow. Additionally, it may block alpha-1 receptors in the central nervous system, reducing sympathetic outflow and ameliorating nightmare-related symptoms in PTSD.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
1 mg orally 2-3 times daily, titrated up to 20 mg/day in divided doses for hypertension; for benign prostatic hyperplasia, 0.5-1 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life: 2-3 hours. However, antihypertensive effect persists for up to 24 hours due to prolonged receptor binding, allowing once-daily dosing.
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Primarily hepatic metabolism (demethylation and conjugation); <10% unchanged in urine; 90% eliminated via bile/feces.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker